$150K Prostate Cancer Drug Draws New Attention to ‘March-In’ Rights
MedPage Today) — In the ongoing debate about how to address skyrocketing prescription drug prices, experts are at odds over whether the federal government should grant “march-in” rights for patents on the prostate cancer drug enzalutamide (Xtandi…
Read More
0
